Grand Pharmaceutical Group Limited (Grand Pharma) has announced a proposal to replace its existing bye-laws with a new set designed to align with forthcoming Hong Kong Stock Exchange (HKEX) regulatory changes.

The board intends to update the governance framework to: • Comply with HKEX’s expanded paperless listing regime. • Enable electronic dissemination of corporate communications to shareholders. • Incorporate the exchange’s new treasury shares provisions. • Facilitate the future implementation of an uncertificated securities market. • Introduce related housekeeping changes for consistency.

The adoption of the revised bye-laws will be put to shareholders as a special resolution at the company’s annual general meeting scheduled for 5 June 2026. A detailed circular outlining the proposed amendments and the AGM notice will be distributed to shareholders in due course.

As of the announcement date (30 April 2026), Grand Pharma’s board consists of four executive directors—Dr. Tang Weikun (Chairman), Mr. Zhou Chao, Mr. Yang Guang and Ms. Lam Chit Yee Jessica—and four independent non-executive directors: Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.